Joint Progression Modeling (JPM): A Probabilistic Framework for Mixed-Pathology Progression Hongtao Hao, Joseph L. Austerweil, for the Alzheimer’s Disease Neuroimaging Initiative * Abstract Event-based models (EBMs) infer disease progression from cross-sectional data, and standard EBMs assume a single underlying disease per individual. In contrast, mixed pathologies are common in neurodegeneration. We introduce the Joint Progression Model (JPM), a probabilistic framework that treats single-disease trajectories as partial rankings and builds a prior over joint progressions. We study several JPM variants (Pairwise, Bradley–Terry, Plackett–Luce, and Mallows) and analyze three properties: (i) calibration —whether lower model energy predicts smaller distance to the ground truth ordering; (ii) separation —the degree to which sampled rankings are distinguishable from random permutations; and (iii) sharpness —the stability of sampled aggregate rankings. All variants are calibrated, and all achieve near-perfect separation; sharpness varies by variant and is well-predicted by simple features of the input partial rankings (number and length of rankings, conflict , and overlap ). In synthetic experiments, JPM improves ordering accuracy by roughly 21% over a strong EBM baseline (SA-EBM) that treats the joint disease as a single condition. Finally, using NACC, we find that the Mallows variant of JPM and the baseline model (SA-EBM) have results that are more consistent with prior literature on the possible disease progression of the mixed pathology of AD and VaD. † † volume: 297 † † year: 2025 † † workshop: Machine Learning for Health (ML4H) 2025 * * footnotetext: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database ( adni.loni.usc.edu ). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found in Appendix A . keywords Neurodegenerative diseases, Disease progression, Event-based model, Rank aggregations, Bayesian inference, Mixed Pathology Data and Code Availability We used both synthetic and real-world datasets (NACC and ADNI). NACC data can be requested through https://naccdata.org , and ADNI via https://adni.loni.usc.edu . We developed a package for JPM, which can be installed via pip install pyjpm . Package source codes can be found at https://github.com/jpcca/pyjpm . Reproducible codes for the experiments in this study are available at https://github.com/hongtaoh/jpm . Institutional Review Board (IRB) The IRB at University of Wisconsin-Madison has reviewed and approved the research (#2025-1254). 1 Introduction Table 1: Participant biomarker measurements ID Impacted ABETA ADAS13 CDRSB Entorhinal FAQ FDG Fusiform Hippocampus LDELTOTAL MMSE MOCA MidTemp PTAU RAVLT TAU TRABSCOR WholeBrain 1 Yes 846.90 13.47 1.64 0.00 -0.17 1.13 0.01 0.01 0.83 30.90 18.41 0.01 11.53 44.87 378.36 124.99 0.74 2 Yes 1187.20 19.92 0.04 0.00 -0.66 1.26 0.02 0.01 5.22 29.12 22.72 0.01 12.32 53.85 113.02 112.70 0.68 3 No 923.78 13.40 -0.10 0.00 2.07 1.30 0.02 0.00 7.18 30.05 22.65 0.01 21.54 43.63 228.85 38.96 0.70 4 Yes 762.25 7.75 0.79 0.00 -0.37 1.22 0.02 0.01 2.66 28.85 19.61 0.01 -3.13 21.16 541.09 78.48 0.68 5 No 506.22 20.85 0.24 0.00 0.48 1.37 0.01 0.00 3.98 28.66 26.52 0.01 14.58 24.91 185.07 114.84 0.68 Note: Biomarker names are abbreviated for brevity. Values of 0.0 result from rounding to two decimal places. Detailed biomarker descriptions are provided in Table 5 (Appendix F ). Modern neuroscience often models the progression of neurodegenerative diseases (NDDs) with frameworks like the Event-Based Model ( 9 ; 47 , EBM,) . These models have provided critical insights into the sequential evolution of biomarkers from cross-sectional data ( 46 ; 45 ; 1 ; 40 ) . They have been successfully applied across multiple diseases, such as Alzheimer’s (AD), frontotemporal dementia, Huntington’s, and Parkinson’s ( 45 ; 9 ; 28 ; 42 ; 8 ) . However, they are built on a simplifying, yet unrealistic, assumption: Each patient suffers from a single, isolated pathology. This assumption is inconsistent with decades of neuropathological evidence. The clinical reality is that patients often have multiple diseases (mixed pathology, or comorbidity), especially in the case of NDDs ( 32 ; 10 ; 5 ; 6 ; 17 ; 36 ; 16 ) . Autopsy studies show that 45.8% of clinically probable AD patients have mixed pathologies such as infarcts, and Lewy bodies ( 33 ) . The rate of mixed pathologies is even higher in Progressive Supranuclear ( 31 , 70%;) and Parkinson’s ( 5 , 84%;) . How can we build models of how diseases jointly progress based on individual disease progression? To illustrate the challenge of modeling mixed pathology progression, consider Table 1 . It contains data of 5 participants (from a larger data set): 3 impacted and 2 healthy. Impacted participants have all triple pathologies: AD, Vascular Dementia (VaD), and Lewy Body Dementia (LBD). Healthy participants are free from all of them. Biomarkers involved in each of the three pathologies are available at Appendix B , and their measurements are continuous. Now the question: what is the ordinal progression of this comorbidity? We define a disease progression as the ordinal order in which biomarkers get pathological. For example, ABETA \to TAU \to MOCA \cdots . Note that we assume all individuals share a common progression for a specific disease. A seemingly straightforward solution would be to treat comorbidity as a unique disease and apply existing models such as EBM from scratch. This approach, however, is both data-inefficient and practically infeasible. It discards the wealth of information available in large single-disease cohorts and imposes unrealistic data requirements. The scale of this data-sparsity problem is starkly illustrated by the National Alzheimer’s Coordinating Center (NACC) dataset, one of the world’s most comprehensive clinical collections for AD and related dementias. While it contains over 13,400 participants with AD alone, only 50 participants with a mixed diagnosis of AD and VaD, and also have the cerebrospinal fluid (CSF) biomarkers essential for modern AD diagnosis and prognosis. (Participants in studies focusing on VaD do not always collect CSF as it can be costly and painful to do so). It is statistically untenable to build a robust progression model from such a small or incomplete sample. In this study, we introduce the Joint Progression Model (JPM), a comprehensive probabilistic framework designed to model mixed pathologies by integrating knowledge from single-disease cohorts. Critically, the JPM is designed for both generative and inferential tasks. This enables not only the generation of synthetic data to probe disease mechanisms and validate models, but also the robust inference of progression and patients’ disease stages. The framework’s core connects joint progression to the rich theoretical literature on probabilistic ranking, e.g., 23 and 30 , using these established models to build a prior within a flexible Bayesian framework that can be paired with any disease progression likelihood function, such as the EBM. In this paper, we make the following contributions. Firstly, we develop the JPM as a theoretical framework for mixed-pathology modeling using the EBM as its likelihood. Secondly, we formally analyze the statistical properties of the JPM, explore how it connects to real-world scenarios, and identify the conditions required for accurate and reliable inference. Lastly, we apply the JPM to both synthetic and real-world datasets, demonstrating up to a 21% improvement in progression estimation accuracy compared to the state-of-the-art single-disease EBM ( 13 ) . 2 Related work The EBM ( 9 ) was a seminal contribution, enabling the inference of biomarker event sequences from cross-sectional data. A family of variants followed, extending the EBM to handle patient heterogeneity ( 40 ) , discover disease subtypes ( 45 ; 12 ) , and scale to high-dimensional data ( 38 ; 43 ) . While alternative frameworks using deep learning on longitudinal data exist for diagnosis predictions ( 18 ; 44 ) , they do not recover event sequences. Crucially, all prior work assumes a single pathology. This single-disease focus is a major limitation, as co-neuropathologies are highly prevalent and clinically significant ( 33 ; 10 ) . To date, modeling mixed pathology progression remains challenging. ( 47 ) . The common practices are to exclude comorbid patients from studies, e.g., in 17 , or predict patient state conversion, e.g., healthy to diseased ( 27 ; 22 ) . Both practices do not allow us to understand how diseases interact as they progress jointly. We propose to fill this gap by applying probabilistic ranking theory ( 39 ) . There exist several possible probabilistic models over rankings or orderings, such as the Mallows ( 23 ) , Bradley-Terry ( 4 ) , and Plackett-Luce models ( 21 ; 30 ) . While widely used in other fields such as election ( 11 ) , consumer preference ( 7 ) , and information retrieval ( 20 ) , these models have not yet been applied to joint disease progression. Below, we demonstrate how we integrate these models into a generative and inference framework to tackle the mixed-pathology problem. 3 JPM theory and algorithms 3.1 Problem statement We define a disease progression as the ordinal sequence in which relevant biomarkers become pathological. We call the progression of an individual disease as a partial ranking , and the progression of the comorbidity as an aggregate ranking . Consider two diseases with their respective progressions: • Disease 1: A \beta \to Tau \to cognitive decline \to hippocampus atrophy • Disease 2: white matter lesions (WML) \to hippocampus atrophy \to cognitive decline The challenge is to determine the most probable aggregate ranking for patients with both diseases. WML \to A \beta \to Tau \to hippocampus atrophy \to cognitive decline is probably more likely than cognitive decline \to atrophy \to WML \to Tau \to A \beta . But by how much? Is it also more probable than WML \to cognitive decline \to A \beta \to Tau \to hippocampus atrophy? A sophisticated model is needed to address these questions when we have multiple partial rankings with biomarkers whose order may conflict across them. Formally, let \mathcal{X}^{(k)} denote the set of biomarkers associated with disease k , with k\in\{1,\ldots,K\} . Let \mathcal{S}=\left(\sigma^{(1)},\sigma^{(2)},...,\sigma^{(K)}\right) denote the K partial rankings, each a total ordering encoding the corresponding (individual) disease’s progression over its biomarkers. Note that this is a partial ranking from the perspective of the comorbidity. Let \mathcal{X}=\bigcup_{k=1}^{K}\mathcal{X}^{(k)} be the set of all unique biomarkers, with m=|\mathcal{X}| . Any aggregate ranking \sigma is a permutation of \mathcal{X} . JPM aims to obtain the posterior of aggregate rankings ( \sigma ) given the observed mixed-pathology data ( D ) and partial rankings ( \mathcal{S} ): P(\sigma\mid D,\mathcal{S})\propto P(D\mid\sigma,\mathcal{S})\,P(\sigma\mid\mathcal{S}) Because \mathcal{S} is fixed ground truth, we can drop it from the data likelihood: P(\sigma\mid D,\mathcal{S})\propto P(D\mid\sigma)\cdot P(\sigma\mid\mathcal{S}) We adopt an energy-based formulation for the prior P(\sigma\mid\mathcal{S}) : P(\sigma\mid\mathcal{S})\propto\exp\left(-E(\sigma\mid\mathcal{S})\right) where E(\sigma\mid\mathcal{S}) is the energy function that assigns a low value to more probable rankings. This exponential form ensures positivity and allows the model to concentrate probability mass around low-energy (i.e., high-likelihood) rankings. Below we describe four principled choices for this energy function 3.2 Variant 1: Pairwise Preferences (PP) The Pairwise Preferences model generalizes majority voting across partial rankings. It treats the energy of aggregate ranking as the outcome of weighted pairwise comparisons between biomarkers. E(\sigma\mid\mathcal{S})=-\sum_{i,j\in\mathcal{X},i\neq j}w_{ij}\mathbf{1}[i<_{\sigma}j] where • \mathbf{1}[i<_{\sigma}j]=1 if i precedes j in ranking \sigma (i.e., i\prec j ); otherwise 0 . • w_{ij} is the weight of preference for i preceding j . We derive w_{ij} from partial rankings: w_{ij}=\sum_{k=1}^{K}\lambda_{k}\cdot r_{k}(i,j),\quad\forall i,j\in\mathcal{X},i\neq j with: • \lambda_{k}\geq 0 is the importance of \sigma^{(k)} (default \lambda_{k}=1 ). • If both i and j are present in \sigma^{(k)} : r_{k}(i,j)=1 when i\prec j , and r_{k}(i,j)=-1 when j\prec i . • r_{k}(i,j)=0 otherwise. 3.3 Variant 2: Generalized Bradley–Terry (BT) The Bradley-Terry model ( 4 ) interpreted rankings as arising from latent strength parameters assigned to each item. Each item i\in\mathcal{X} is associated with a parameter \theta_{i} , forming a vector of \vec{\theta} . The probability of i preceding j is: P(i\prec j)=\frac{e^{\theta_{i}}}{e^{\theta_{i}}+e^{\theta_{j}}} Let C_{i,j} be the number of times of i\prec j across all partial rankings. If i and j are never jointly observed, or i never precedes j , then C_{i,j}=0 . For a partial ranking \sigma^{(k)}=\left(\sigma_{1}^{(k)},\sigma_{2}^{(k)},\ldots,\sigma_{n_{k}}^{(k)}\right) , its likelihood is: p(\sigma^{(k)}\mid\vec{\theta})=\prod_{i,j\in T^{(k)},i\prec j}P(i\prec j)^{C_{i,j}} where T^{(k)} is the set of all pairs of items in \sigma^{(k)} . The log-likelihood is: \log p(\sigma^{(k)}\mid\vec{\theta})=\sum_{i,j\in T^{(k)},i\prec j}C_{i,j}\cdot\left(\theta_{i}-\log(e^{\theta_{i}}+e^{\theta_{j}})\right) Maximizing the total log-likelihood yields parameter estimates: \hat{\vec{\theta}}=\arg\max_{\theta}\sum_{k=1}^{K}\log P(\sigma^{(k)}|\vec{\theta}) The corresponding energy for an aggregate ranking \sigma is: E(\sigma\mid\mathcal{S})=E(\sigma\mid\hat{\vec{\theta}})=-\log P(\sigma^{(k)}\mid\vec{\hat{\theta}}) 3.4 Variant 3: Plackett–Luce (PL) The Plackett-Luce model ( 30 ; 21 ) generates rankings sequentially, choosing one item at a time with probability proportional to an associated score. Each item i\in\mathcal{X} has a parameter \alpha_{i} . For a partial ranking \sigma^{(k)}=[x_{1},x_{2},\ldots,x_{n_{k}}] , where n_{k}\leq m and \{x_{1},x_{2},\ldots,x_{n_{k}}\}\subseteq\mathcal{X} : P(\sigma^{(k)}\mid\vec{\alpha})=\prod_{t=1}^{n_{k}}\frac{e^{\alpha_{x_{t}}}}{\sum_{j=t}^{n_{k}}e^{\alpha_{x_{j}}}} The log-likelihood is: \log P(\sigma^{(k)}\mid\vec{\alpha})=\sum_{t=1}^{n_{k}}\left(\alpha_{x_{t}}-\log\sum_{j=t}^{n_{k}}e^{\alpha_{x_{j}}}\right) Parameters are estimated via maximum likelihood: \hat{\vec{\alpha}}=\arg\max_{\alpha}\sum_{k=1}^{K}\log P(\sigma^{(k)}|\vec{\alpha}) For an aggregate ranking \sigma=[y_{1},y_{2},\ldots,y_{m}] , the energy is: E(\sigma\mid\mathcal{S})=E(\sigma\mid\vec{\hat{\alpha}})=-\log P(\sigma^{(k)}\mid\vec{\hat{\alpha}}) 3.5 Variant 4: BT-informed Mallow’s Model The Mallows model ( 23 ) places probability mass around a central ranking \sigma_{0} : P(\sigma)\propto\exp(-\theta\cdot d(\sigma,\sigma_{0})) where d(\cdot,\cdot) is a distance metric (e.g., Kendall’s tau or Reverse Major Index ( 7 , RMJ;) ). Dispersion \theta controls how concentrated the distribution is. The challenge is inferring \theta and \sigma_{0} from a small number of heterogeneous partial rankings. Existing methods, for instance, BayesMallows ( 41 ; 37 ) , require richer data and are unstable when only 2-4 partial rankings are available—typical in mixed-pathology settings. In our preliminary experiments, estimated central rankings given a fixed set of partial rankings varied greatly across runs (Kendall’s W \approx 0.1), while BT produced stable estimates ( >0.9 ). We decide to use the inference method from BT to provide an estimate of \sigma_{0} and set \theta manually, which we call BT-informed Mallows model . The energy for the BT-informed Mallows model is: E(\sigma\mid\mathcal{S})=\theta\cdot d(\sigma,\sigma_{0}) where the dispersion \theta provides a flexible knob for synthetic data generation: larger \theta yields a more peaked distribution on the central ordering \sigma_{0} , and smaller \theta yields a more uniform distribution over \sigma . 3.6 Generative and inference algorithms JPM can be used for both generative and inferential purposes. With a defined JPM, we can define algorithms for generating aggregate rankings based on input partial rankings, which is crucial for creating synthetic data. We can also infer the aggregate rankings from a data set (Algorithm C in Appendix C ). In terms of generating aggregate rankings, PL sampling is straightforward, as rankings are generated sequentially (See Algorithm C ). Other models (PP, BT, Mallows) do not admit direct sampling. We employ Metropolis-Hastings MCMC ( 24 ; 14 ) , starting from a random permutation and proposing swaps between positions (See Algorithm C ). Note that MCMC can be applied to PL as well. Throughout the paper, we used Kendall’s \tau as the distance metric. 4 Theoretical analysis We explored five key questions regarding the JPM framework: Q1: Is JPM valid as an inference model? Q2: Is JPM valid as a generative model? Q3: Which JPM variants are suitable for synthetic data generation? Q4: For a given dataset, should JPM be preferred over a single-disease model for inference (e.g., SA-EBM ( 13 ) )? Q5: If JPM is appropriate for inference, which variant should be used? This section addresses the first three questions. Q4 and Q5 will be addressed in the Discussion. 4.1 Q1: Model calibration JPM as an inference algorithm aims to correctly assign energies to different aggregate rankings. We define a “valid inference model” as one that assigns low energies to aggregate rankings with smaller distances from the ground truth aggregate ranking ( \sigma_{\text{gt}} ). Formally, for any two candidate rankings \sigma_{A} and \sigma_{B} , a well-behaved model should satisfy the condition: E_{\text{JPM}}(\sigma_{A})\ell^{\star} \sigma^{\star}\leftarrow\sigma , \ell^{\star}\leftarrow\ell \Return \sigma^{\star} Explanations: • The energy function is one of the required inputs. This means we need to decide on the JPM variant. • We use EBM as the data likelihood function, i.e., P(D_{m-p}\mid\sigma) and \log P(D_{m-p}\mid\sigma) . More specifically, we used SA-EBM ( 13 ) . Note that EBM is just one choice for the likelihood function. Future work can explore other possible likelihoods. • In the estimation of partial rankings from individual diseases’ data, we also used SA-EBM ( 13 ) , which has state-of-the-art performance on estimating ordinal disease progressions from cross-sectional datasets. {algorithm2e} [htbp] Plackett–Luce Sampling \KwIn Parameters \vec{\alpha}=(\alpha_{1},\dots,\alpha_{m}) \KwOut Aggregate ranking \sigma=[i_{1},i_{2},\dots,i_{m}] \For t=1 \KwTo m \tcp Sample next item proportional to its weight \tcp \mathcal{X} is the list of biomarkers in the aggregate ranking, whose length is m Sample i_{t} with probability \displaystyle\frac{e^{\alpha_{i}}}{\sum_{q\in\mathcal{X}}e^{\alpha_{q}}} \tcp Remove item from available set U\leftarrow\mathcal{X}\setminus\{i_{t}\} \Return \sigma=[i_{1},i_{2},\dots,i_{m}] {algorithm2e} [htbp] JMP Generative Algorithm (Metropolis–Hastings MCMC) \KwIn Set \mathcal{X} , Energy function E(\sigma) \KwOut Best aggregate ranking \sigma^{\star} \tcp Init \sigma\leftarrow random permutation of \mathcal{X} \ell\leftarrow E(\sigma) \sigma^{\star}\leftarrow\sigma , \ell^{\star}\leftarrow\ell \For t=1 \KwTo T \tcp Step 1: Proposal Propose \sigma^{\prime}\leftarrow swap two random items in \sigma \tcp Step 2: Compute energy \ell^{\prime}\leftarrow E(\sigma^{\prime}) \tcp Step 3: Metropolis-Hastings acceptance probability p\leftarrow\min(1,\exp(\ell-\ell^{\prime})) Draw u\sim\text{Uniform}(0,1) \tcp Step 4: Accept/Reject \If u

0 concordant\leftarrow concordant+1 \If (r_{1}[p]-r_{1}[q])\cdot(r_{2}[p]-r_{2}[q])<0 discordant\leftarrow discordant+1 total\leftarrow concordant+discordant \If total=0 \Return 0 \Else \Return \displaystyle\frac{discordant}{total} Appendix E Model Analysis Table 4: Regression Models Predicting Model Sharpness PL BT Pairwise Mallows \theta=1.0 Mallows \theta=10.0 (1) (2) (3) (4) (5) const 1.142*** 1.013*** 0.942*** 1.082*** 1.240*** (0.015) (0.002) (0.010) (0.005) (0.005) n_{pr} -0.003 -0.000 0.001 -0.113*** -0.121*** (0.002) (0.000) (0.001) (0.001) (0.001) mean_len 0.004*** 0.001*** 0.002** -0.047*** -0.048*** (0.001) (0.000) (0.001) (0.000) (0.001) conflict -0.257*** -0.030*** -0.116*** -0.001 0.002 (0.008) (0.001) (0.006) (0.002) (0.003) overlap_rate -0.567*** -0.073*** -0.095*** 0.283*** 0.292*** (0.008) (0.001) (0.006) (0.005) (0.005) R^{2} 0.651 0.630 0.193 0.858 0.852 Adj. R^{2} 0.650 0.629 0.192 0.858 0.851 N 3240 3240 3240 3240 3240 Standard errors in parentheses. * p < 0.1, ** p < 0.05, *** p < 0.01 In Table 4 , n_{pr} refers to the number of partial rankings, and mean_len indicates the average number of partial rankings. Figure 1: Distribution of calibration by generative and inference JPM variant Figure 2: Separation and sharpness of different JPM variants Figure 3: Correlation between sharpness and input partial ranking characteristics when the aggregate rankings are generated with the BT variant Figure 4: Correlation between sharpness and input partial ranking characteristics when the aggregate rankings are generated with the PL variant Figure 5: Correlation between sharpness and input partial ranking characteristics when the aggregate rankings are generated with the PP variant Figure 6: Correlation between sharpness and input partial ranking characteristics when the aggregate rankings are generated with the Mallows ( \theta=1 ) variant Figure 7: Correlation between sharpness and input partial ranking characteristics when the aggregate rankings are generated with the Mallows ( \theta=10 ) variant Appendix F Biomarkers for synthetic experiments This is how we processed the ADNI data and obtained the parameters reported in Table 6 . We obtained the adnimerge table (Version: September 7, 2023) from the Alzheimer’s Disease Cooperative Study data system. We only included the baseline visits from participants with a diagnosis of CN, Early and Late MCI, or AD. For brain region MRI values, we applied intracranial volume (ICV) normalization because people have different brain sizes. We excluded participants with any missing values from any of the 18 biomarkers reported in Table 5 . After de-duplicating the final dataset, we had 420 participants with 350 (83.3%) from the protocol of ADNI2 and 70 (18.3%) from ADNIGO. The distribution of diagnosis of these 420 participants is: • AD: 67 (16.0%) • EMCI: 175 (41.7%) • LMCI: 101 (24.0%) • CN: 77 (18.3%) We then applied SA-EBM ( 13 ) (the Conjugate Priors variant) to obtain the biomarker distribution parameters reported in Table 6 . Table 5: Glossary of Biomarkers with Source, Units, and Interpretation Abbrev. Full Name Source Unit / Scale Higher Values Indicate ABETA Amyloid Beta (A \beta_{1-42} ) CSF pg/mL Less pathology (less amyloid) ADAS13 ADAS-Cog (13-item) Cognitive test 0–85 More pathology (worse cognition) CDRSB CDR Sum of Boxes Clinical rating 0–18 More pathology (greater severity) EntorhinalNorm Entorhinal Volume (norm.) MRI Ratio Less pathology (greater volume) FAQ Functional Activities Q. Informant test 0–30 More pathology (worse function) FDG FDG-PET (PCC/precuneus) PET SUVR Less pathology (better metabolism) FusiformNorm Fusiform Volume (norm.) MRI Ratio Less pathology (greater volume) HippocampusNorm Hippocampal Volume (norm.) MRI Ratio Less pathology (greater volume) LDELTOTAL Logical Memory II (Delayed) Cognitive test 0–25 Less pathology (better recall) MMSE Mini-Mental State Exam Cognitive test 0–30 Less pathology (better cognition) MOCA Montreal Cognitive Assessment Cognitive test 0–30 Less pathology (better cognition) MidTempNorm Middle Temporal Volume (norm.) MRI Ratio Less pathology (greater volume) PTAU Phosphorylated Tau 181 CSF pg/mL More pathology (tangle burden) RAVLT-immediate Rey Auditory Verbal Learning (Immediate) Cognitive test 0–75 Less pathology (better memory) TAU Total Tau CSF pg/mL More pathology (axonal injury) TRABSCOR Trail Making Test B Cognitive test Seconds More pathology (slower exec. func.) VentricleNorm Ventricular Volume (norm.) MRI Ratio More pathology (ventricular enlarge.) WholeBrainNorm Whole Brain Volume (norm.) MRI Ratio Less pathology (greater volume) Table 6: Biomarker Parameterization and Non-Normal Sampling Distributions Biomarker \theta_{\text{mean}} \theta_{\text{std}} \phi_{\text{mean}} \phi_{\text{std}} Non-normal Distribution (Per Implementation) Cognitive / Functional Measures MMSE 24.74 2.26 28.75 1.30 Triangular (\mu-2\sigma,\mu-1.5\sigma,\mu) ; \mathcal{N}(\mu+\sigma,(0.3\sigma)^{2}) ; Exp (0.7\sigma)+(\mu-0.5\sigma) (equal mixture). ADAS13 26.09 7.77 11.22 4.83 Same mixture structure as MMSE (triangular + Gaussian + exponential). RAVLT_immediate 25.00 6.39 41.70 10.42 Same mixture structure as MMSE. CDRSB 2.12 1.66 0.04 0.16 Same mixture structure as MMSE. FAQ 8.12 6.54 0.52 0.90 Same mixture structure as MMSE. LDELTOTAL 2.95 2.82 9.77 3.53 Same mixture structure as MMSE. MOCA 18.85 3.52 24.46 2.62 Same mixture structure as MMSE. TRABSCOR 276.62 32.45 97.77 43.00 Same mixture structure as MMSE. CSF Biomarkers & FDG ABETA 712.35 240.58 1077.89 353.53 Pareto(1.5) \cdot\sigma+(\mu-2\sigma) ; \mathcal{U}(\mu-1.5\sigma,\mu+1.5\sigma) ; Logistic (\mu,\sigma) (equal mixture). TAU 350.36 148.44 211.02 78.13 Same mixture structure as ABETA. PTAU 34.99 16.15 19.46 8.24 Same mixture structure as ABETA. FDG 1.09 0.12 1.29 0.12 Same mixture structure as ABETA. Subcortical Volumes VentricleNorm 0.03256 0.01228 0.02064 0.00929 Beta(0.5,0.5) \cdot 4\sigma+(\mu-2\sigma) ; Exp (0.4\sigma) with \pm sign; \mathcal{N}(\mu,(0.5\sigma)^{2}) + {0, 2\sigma } spike. HippocampusNorm 0.00394 0.00053 0.00502 0.00059 Same mixture structure as VentricleNorm. Cortical Atrophy Measures WholeBrainNorm 0.66854 0.03340 0.71070 0.03502 Gamma (2,0.5\sigma)+(\mu-\sigma) ; Weibull (1.0)\cdot\sigma+(\mu-\sigma) ; \mathcal{N}(\mu,(0.5\sigma)^{2})\pm\sigma . EntorhinalNorm 0.001997 0.000401 0.002576 0.000377 Same mixture structure as WholeBrainNorm. FusiformNorm 0.01095 0.00127 0.01255 0.00131 Standard Cauchy (\mu,\sigma) + \mathcal{N}(0,(0.2\sigma)^{2}) , clipped to [\mu-4\sigma,\mu+4\sigma] . MidTempNorm 0.01205 0.00145 0.01397 0.00129 10% \mathcal{N}(\mu,0.2\sigma) spike + 90% Logistic (\mu+\sigma,2\sigma) . Implementation Notes: After sampling, all values are perturbed by additional noise \mathcal{N}(0,(0.2\sigma)^{2}) and clipped to [\mu-5\sigma,\mu+5\sigma] for stability. Appendix G Experimental setup Table 7: Summary of nine simulation experiments. S denotes the event sequence, k_{j} the participant stage distribution, and X the biomarker distribution. Exp. Event Sequence ( S ) Stage Distribution ( k_{j} ) Biomarker Distribution ( X ) 1 Ordinal Dirichlet-Multinomial (bell-shaped) Normal 2 Ordinal Dirichlet-Multinomial (bell-shaped) Non-Normal 3 Ordinal Uniform (discrete) Normal 4 Ordinal Uniform (discrete) Non-Normal 5 Ordinal Continuous Uniform Normal 6 Ordinal Continuous Uniform Non-Normal 7 Ordinal Continuous Skewed (Beta, \alpha=5,\;\beta=2 ) Non-Normal 8 Ordinal Continuous Uniform Sigmoid for diseased; Normal for healthy 9 Ordinal Continuous Skewed (Beta, \alpha=5,\;\beta=2 ) Sigmoid for diseased; Normal for healthy Appendix H Sigmoid Model The Sigmoid model assumes that biomarker values for control individuals are normally distributed: x\sim\mathcal{N}(\mu_{\phi},\sigma^{2}_{\phi}), where \mu_{\phi} and \sigma^{2}_{\phi} denote the mean and variance in the healthy state, respectively. For participants affected by disease, the biomarker distribution is shifted away from this baseline according to a smooth, sigmoidal transition: x\sim\mathcal{N}(\mu_{n,\phi},\sigma^{2}_{n,\phi})\;+\;\frac{(-1)^{I_{n}}R_{n}}{1+\exp\!\left(-\rho_{n}(k_{j}-\xi_{n})\right)}, where I_{n}\sim\text{Bernoulli}(0.5) randomly determines the direction of the shift, R_{n}=\mu_{n,\theta}-\mu_{n,\phi} specifies the magnitude of separation between disease and control means, and the slope parameter is given by \rho_{n}=\max\!\left(1,\;\frac{|R_{n}|}{\sqrt{\sigma^{2}_{n,\theta}+\sigma^{2}_{n,\phi}}}\right). Appendix I Synthetic experiment results Figure 8: Average normalized Kendall’s Tau ( \pm 95\% CI) for data generated by PP . Each panel displays a different experiment with varying configurations represented by the panel title. The X-axis of each subplot shows participant sizes ( J=50,100,200 ). For each participant size, there are three different healthy ratios ( 0.25,0.5,0.75 , from left to right). The Y-axis is the normalized Kendall’s tau distance. A lower tau indicates the estimation is closer to the ground truth. Data points represent mean performance across 10 variants of the same experimental configurations, participant size, and healthy ratio. JPM (except for Mallows with \theta=1.0 ) outperforms the single-disease EBM model, achieving a 21% increase in the performance of the ordering task. This advantage is consistent across experiments, participant sizes, and healthy ratios, but more pronounced when J is small. Figure 9: MAE (staging) for PP generated data Figure 10: Kendall’s tau distance (ordering) for BT generated data Figure 11: MAE (staging) for BT generated data Figure 12: Kendall’s tau distance (ordering) for PL generated data Figure 13: MAE (staging) for PL generated data Figure 14: Kendall’s tau distance (ordering) for Mallows (dispersion = 1.0) generated data Figure 15: MAE (staging) for Mallows (dispersion = 1.0) generated data Figure 16: Kendall’s tau distance (ordering) for Mallows ( \theta = 10.0) generated data Figure 17: MAE (staging) for Mallows ( \theta = 10.0) generated data Appendix J NACC Data Preprocessing Pipeline This appendix provides a comprehensive description of the data processing pipeline used to select and prepare the National Alzheimer’s Coordinating Center (NACC) dataset for our real-world experiments. The process involved three main stages: cohort definition, biomarker data integration, and final data transformation. The following data are needed: • UDS with NP and Genetics plus FTLD and LBD modules: ftldlbd_nacc70.csv • CSF: fcsf_nacc70.csv • Phenotype Harmonization Consortium (PHC) scores with NACCID and visit number: ADSP-PHC_Cognition_NACC_DS_Freeze1.csv • Mixed protocol (non-SCAN compliant) MRI: investigator_mri_nacc70.csv J.1 Initial Data Loading and Cohort Definition The first stage focused on identifying distinct diagnostic cohorts from the primary NACC dataset. Data Loading and Subject Uniqueness We began with the NACC dataset file ftldlbd_nacc70.csv , which contained longitudinal data for 54,631 unique participants . To create a cross-sectional dataset for our analysis, we filtered these records to retain only the earliest visit for each participant, identified by NACCVNUM = 1 . Pathological Cohort Identification We then defined four primary pathological cohorts by creating Boolean flags based on a combination of clinical diagnosis and derived NACC variables. A participant was considered positive for a pathology if they met any of the criteria listed below: • Alzheimer’s Disease (AD): PROBAD=1 , POSSAD=1 , NACCALZP=1 , or NACCALZD=1 . • Lewy Body Dementia (LBD): NACCLBDP=1 or NACCLBDE=1 . • Frontotemporal Lobar Degeneration (FTLD): NACCFTD=1 , FTD=1 , FTLDNOS=1 , or FTLDMO=1 . • Vascular Dementia (VaD): NACCVASC=1 , VASC=1 , or CVD=1 . J.2 Biomarker Data Integration and Filtering The second stage involved merging and filtering data from three separate biomarker files to enrich the primary dataset. Cerebrospinal Fluid (CSF) Data We loaded CSF biomarker data from nacc_csf.csv . To ensure data quality and relevance, we applied two key filters. First, we selected only baseline visit records. Second, because CSF sample dates do not always align perfectly with clinical visit dates, we implemented a temporal window, associating a CSF sample with a visit only if the sample was taken within 180 days of the visit date. The resulting data was then merged with our main participant dataframe. Phenotype Harmonization Consortium (PHC) Data Again, we selected only baseline visit records. This dataset was then merged directly with the main dataframe using the participant ID as the key. MRI Volumetric Data Structural MRI data was loaded from mri_vol.csv . We filtered this dataset to include only baseline MRI scans before merging it with the main dataframe on the participant ID. J.3 Final Cohort Analysis and Data Availability After successfully merging all data sources, we finalized the cohorts and quantified the availability of biomarker data across them. Creation of Mutually Exclusive Cohorts Using the pathological flags defined earlier, we created a set of mutually exclusive cohorts. This allowed us to distinguish between participants with a single pathology (e.g., AD only ) and those with mixed pathologies (e.g., AD VaD ). Layered Availability Analysis We generated boolean flags for each participant to indicate the presence of valid data for each biomarker type ( has_csf , has_phc , has_mri ). We then systematically counted the number of participants within each mutually exclusive cohort that had each possible combination of these data types. The results of this analysis are presented in Table 8 , which provides a detailed view of data completeness across the study population. J.4 Data Transformation for Modeling As a final preprocessing step, the fully integrated and filtered dataframe, which was in a wide format (one column per biomarker), was transformed into a long format using the pandas.melt function. This reshaping is a standard and necessary step to structure the data appropriately for subsequent statistical modeling and analysis. The final overall data availability after our processing is displayed in Table 8 . The biomarkers chosen for AD and VaD, with detailed information about each biomarker, are available in Table 9 . Table 8: Layered Availability of NACC Data Across Cohorts. This table shows the total number of participants in each diagnostic cohort and the count of participants for whom specific data types (MRI, CSF, PHC) are available, both individually and in combination. Cohort Total +MRI +CSF +PHC +MRI+PHC +CSF+MRI +CSF+PHC +CSF+MRI+PHC healthy 26355 4593 1094 18119 3746 234 990 205 AD_only 13400 1656 463 10023 1474 87 413 82 AD_VaD 4449 630 276 3448 578 53 255 50 VaD_only 3903 581 246 3171 532 40 236 36 FTLD_only 2379 146 27 1024 93 6 17 5 LBD_only 1140 89 30 835 74 5 24 5 FTLD_VaD 817 50 10 505 35 1 4 1 AD_FTLD 682 39 19 333 27 4 14 3 AD_LBD 516 48 12 358 43 4 11 3 LBD_VaD 422 64 20 341 58 2 16 2 AD_LBD_VaD 278 27 10 211 24 1 10 1 AD_FTLD_VaD 227 12 8 150 11 0 5 0 FTLD_LBD 26 0 0 12 0 0 0 0 AD_FTLD_LBD 15 0 0 7 0 0 0 0 FTLD_LBD_VaD 13 0 0 6 0 0 0 0 AD_FTLD_LBD_VaD 9 0 0 5 0 0 0 0 Table 9: Glossary of NACC Biomarkers with Source, Units, and Interpretation Abbrev. Full Name Source Unit / Scale Higher Values Indicate AD VaD ptau_abeta Phospho-Tau 181 /A \beta_{1-42} ratio CSF Ratio More pathology (higher tau-to-amyloid) True False ttau_abeta Total Tau/A \beta_{1-42} ratio CSF Ratio More pathology (higher tau-to-amyloid) True False CSFABETA Amyloid Beta (A \beta_{1-42} ) CSF pg/mL Less pathology (lower deposition) True False CSFPTAU Phosphorylated Tau 181 CSF pg/mL More pathology (tangle burden) True False CSFTTAU Total Tau CSF pg/mL More pathology (neurodegeneration) True False HippVolNorm Hippocampal Volume (normalized) MRI Ratio Less pathology (larger volume) True False EntorhinalNorm Entorhinal Volume (normalized) MRI Ratio Less pathology (larger volume) True False MidTempNorm Middle Temporal Volume (normalized) MRI Ratio Less pathology (larger volume) True False FusiformNorm Fusiform Volume (normalized) MRI Ratio Less pathology (larger volume) True False WholeBrainNorm Whole Brain Volume (normalized) MRI Ratio Less pathology (larger volume) True True VentricleNorm Ventricular Volume (normalized) MRI Ratio More pathology (enlargement) True True WMHnorm White Matter Hyperintensity (normalized) MRI Ratio More pathology (greater burden) False True PHC_MEM Harmonized Composite Memory Score Cognitive composite z-score Better cognition True True PHC_EXF Harmonized Composite Executive Function Cognitive composite z-score Better cognition True True PHC_LAN Harmonized Composite Language Score Cognitive composite z-score Better cognition True True We included the two ratios, i.e., ptau_abeta and ttau_abeta because 29 found that these ratios have higher diagnostic power for Alzheimer’s disease than raw Abeta values. Appendix K NACC results Figure 18: Progression of AD, obtained via SA-EBM Figure 19: Progression of VaD, obtained via SA-EBM Figure 20: Progression of the mixed pathology of AD and VaD, obtained via SA-EBM Figure 21: Progression of the mixed pathology of AD and VaD, obtained via JPM (BT) Figure 22: Progression of the mixed pathology of AD and VaD, obtained via JPM (PP) Figure 23: Progression of the mixed pathology of AD and VaD, obtained via JPM (PL) Figure 24: Progression of the mixed pathology of AD and VaD, obtained via JPM (Mallows) Figure 25: Trace plot of running SA-EBM on the mixed-pathology data Figure 26: Trace plot of running JPM-Mallows on the mixed-pathology data